REG1

DRUG3 trials

Sponsors

National Heart, Lung, and Blood Institute (NHLBI), Regado Biosciences, Inc.

Conditions

Acute Coronary Syndrome (ACS)Coronary Artery DiseaseHealthy

Phase 1

Safety and Dosing Evaluation of REG1 Anticoagulation System

CompletedNCT00113997

National Heart, Lung, and Blood Institute (NHLBI)Healthy

Start: 2005-06-30End: 2005-10-31Target: 106Updated: 2008-03-04

Phase 2

Feasibility and Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Elective PCI

CompletedNCT00715455

Regado Biosciences, Inc.Coronary Artery Disease

Start: 2007-10-31End: 2008-10-31Updated: 2013-05-31

A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome

CompletedNCT00932100

Regado Biosciences, Inc.Acute Coronary Syndrome (ACS)

Start: 2009-07-31End: 2011-01-31Updated: 2012-03-02

Related Papers

Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study

EuroIntervention2014-08-0127 citations

Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design.

2011-07-0121 citations

First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention.

2010-07-2671 citations